Clinical Takeaway
In this phase 3 randomized controlled trial of 820 adults, the full-spectrum cannabis extract VER-01 was evaluated against placebo over 12 weeks for chronic low back pain, with extended follow-up lasting up to one year. The trial was designed to assess both efficacy and safety across multiple phases, providing unusually robust long-term data for a cannabis-based intervention in this population.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by rigorously evaluating a full-spectrum cannabis extract for chronic low back pain, a condition affecting over 500 million people globally with existing pharmacologic options limited by poor efficacy and adverse risk profiles. The large sample size (n=820) and randomized placebo-controlled design with extended follow-up provide robust evidence to establish whether cannabis-derived therapeutics offer a viable alternative for the substantial proportion of CLBP patients who fail conventional treatments. If VER-01 demonstrates efficacy and favorable safety, this work could support clinical integration of standardized cannabis medicines into pain management algorithms while informing regulatory pathways for cannabinoid-based therapeutics.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
💊 This phase 3 trial presents meaningful data on full-spectrum cannabis extract for chronic low back pain, a condition where conventional analgesics often disappoint patients and clinicians alike, though several important considerations warrant careful interpretation. The 820-participant sample size and randomized placebo-controlled design represent a substantial improvement in cannabis research methodology, yet the incomplete abstract prevents assessment of primary outcome magnitude, statistical significance, and whether observed benefits justify potential risks or drug interactions in our diverse patient populations. Key confounders to consider include baseline pain severity heterogeneity, concurrent medication use, prior cannabis exposure, and whether the open-label extension phase (mentioned but not detailed) may have introduced expectancy bias that inflates perceived efficacy. For clinical practice, this trial merits attention as part of a growing evidence base, but practitioners should await full publication to evaluate effect sizes, adverse event profiles, and subgroup analyses before incorporating VER-01 into chronic pain algorithms; meanwhile, continued emphasis on multimodal approaches including physical therapy, psychological support, and judicious